India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,233 Swapnil Jatin Shah ₹1,900 Cr
Market Cap
₹5,538 Cr
SENORES · NSE
Share Price
₹1,215.30
+1.06% today
Revenue
₹633 Cr
FY 2025-26 · +58.9% YoY
EBITDA
₹168 Cr
Margin 26.6%
Net Profit
₹115 Cr
FY 2025-26 · +97.0% YoY
P/E (TTM)
44.6x
P/B 6.0x
Authorised capital
₹59 Cr
Registered with MCA
Paid-up capital
₹46.05 Cr
Issued & subscribed
About Senores Pharmaceuticals Limited
Data last updated:
Senores Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 26 December 2017 and has been in existence for over 9 years.
Its director Swapnil Jatin Shah is #1,233 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24290GJ2017PLC100263. Its GSTIN is 24AAZCS6422N1ZK (Gujarat). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 544319 and NSE: SENORES.
The company has an authorised share capital of ₹59 Cr and a paid-up capital of ₹46.05 Cr. It is led by directors including Swapnil Jatinbhai Shah (Managing Director) and Deval Rajnikant Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 18 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 1101 To 1103 11th Floor South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road, Ahmedabad, Gujarat, India – 380054.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹632.63 Cr, a growth of 58.9% compared to the previous year. For the same year it recorded a net profit of ₹115.36 Cr (net margin 18.2%) and EBITDA of ₹168.32 Cr (EBITDA margin 26.6%).
The company has about 120 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Senores Pharmaceuticals. As per MCA filings, the company has open charges of ₹210.24 Cr and satisfied charges of ₹130.75 Cr on record. Court records list 3 cases involving the company, including 3 filed by the company; 3 cases are pending. The company has 18 deals on record (11 market trades, 4 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹28.28 Cr; the latest was in December 2025. Its 7 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 5 smaller; the largest is Olon Active Pharmaceutical Ingredients India Private Limited with revenue of ₹431.21 Cr. The company has 7 MSME Form 1 returns on record between 2021 and 2024, listing 58 overdue payments to 12 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website senorespharma.com.
Company details
CIN L24290GJ2017PLC100263
Registration Number 100263
Incorporation Date 26 December 2017
ROC Ahmedabad
Listing Status Listed - Listed on NSE (SENORES); Listed on BSE (544319)
Company Status Active
Date of Last AGM 18 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Udyam Registration UDYAM-GJ-01-0052884
CIN history
Senores Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24290GJ2017PLC100263, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24290GJ2017PLC100263 | Current |
| U24290GJ2017PTC100263 | Previous |
| U24290GJ2017PLC100263 | Previous |
Key People
Swapnil Jatinbhai Shah Managing Director Deval Rajnikant Shah Whole-Time Director Chetan Bipinchandra Shah Whole-Time Director Recognitions & Rankings of Senores Pharmaceuticals
Contact details
Senores Pharmaceuticals Limited's registered office is in Ahmedabad, Gujarat. Its website is senorespharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address1101 To 1103 11th Floor South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road, Ahmedabad, Gujarat, India – 380054
- IndustryPharma, API Manufacturers
To see the full contact details of Senores Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Senores Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Senores Pharmaceuticals operates one associated brand: Senores Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical drugs are manufactured by Senores Pharmaceuticals. | senorespharma.com |
Business activity
The main business activity of Senores Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Senores Pharmaceuticals Limited, buy the company report.
Financials of Senores Pharmaceuticals Limited
FY 2025-26 filings availableSenores Pharmaceuticals Limited reported revenue of ₹632.63 Cr (up 58.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹633 Cr
+58.9% YoY
EBITDA
₹168 Cr
+87.6% YoY
Profit After Tax
₹115 Cr
+97.0% YoY
Net Worth
-
Total Assets
-
Total Debt
-
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 633 | 398 | 215 | 35.34 | 14.17 |
| Revenue growth | +58.9% | +85.7% | +507.0% | +149.4% | - |
| EBITDA | 168 | 89.70 | 41.59 | 12.68 | 1.96 |
| EBITDA margin | +26.6% | +22.5% | +19.4% | +35.9% | +13.8% |
| Profit before tax | 159 | 70.57 | 24.94 | 12.44 | 1.14 |
| Net profit | 115 | 58.56 | 31.48 | 8.43 | 0.99 |
| Net profit margin | +18.2% | +14.7% | +14.7% | +23.9% | +7.0% |
| EPS (₹) | 26.39 | 12.72 | 10.31 | 8.59 | 1.13 |
| Balance sheet | |||||
| Total assets | - | 1,130 | 491 | 108 | 51.40 |
| Net worth | - | 786 | 204 | 45.50 | 36.59 |
| Total debt | - | 315 | 258 | 62.60 | 14.75 |
| Cash & bank | - | 386 | 13.06 | 0.10 | 3.22 |
| Net working capital | - | 626 | 120 | 30.73 | 19.29 |
| Cash flow | |||||
| Cash from operations | - | (45.92) | (25.70) | (1.08) | (10.45) |
| Cash from investing | - | (429) | (53.73) | (48.29) | (24.44) |
| Cash from financing | - | 573 | 86.98 | 46.25 | 36.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 180 | 175 | 171 | 162 | 133 | 114 | 103 | 101 |
| Revenue growth (YoY) | +36.0% | +53.4% | +65.9% | +60.8% | +64.9% | - | - | - |
| Other income | 2.81 | 17.67 | 7.39 | 5.41 | 8.79 | 11.77 | 5.16 | 1.86 |
| EBITDA | 53.76 | 47.49 | 50.40 | 49.51 | 28.73 | 19.44 | 25.69 | 23.27 |
| EBITDA margin | +29.8% | +27.1% | +29.5% | +32.3% | +21.7% | +17.0% | +24.9% | +23.7% |
| Depreciation | 9.94 | 9.30 | 7.86 | 8.09 | 5.99 | 5.23 | 4.20 | 3.89 |
| Interest | 7.17 | 8.46 | 5.33 | 6.19 | 5.04 | 5.30 | 6.16 | 5.27 |
| Profit before tax | 39.46 | 47.40 | 44.60 | 40.64 | 26.49 | 20.68 | 20.49 | 15.97 |
| Tax | 9.01 | 10.73 | 11.02 | 10.52 | 5.31 | 2.71 | 4.06 | 2.90 |
| Net profit | 30.45 | 36.67 | 33.58 | 30.12 | 21.18 | 17.97 | 16.43 | 13.07 |
| EPS (₹) | 6.60 | 7.96 | 7.29 | 6.54 | 4.60 | 3.81 | 5.04 | 3.92 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 106 | 38.54 | 34.01 | 12.38 | 13.54 | 7.91 |
| Revenue growth | +175.3% | +13.3% | +174.7% | -8.6% | +71.2% | - |
| EBITDA | (18.68) | (7.28) | (0.06) | (1.78) | 1.16 | 1.01 |
| EBITDA margin | -17.6% | -18.9% | -0.2% | -14.4% | +8.6% | +12.8% |
| Profit before tax | 27.46 | 5.11 | 2.03 | 1.94 | 0.83 | 0.39 |
| Net profit | 20.25 | 3.69 | 0.81 | 1.20 | 0.68 | 0.83 |
| Net profit margin | +19.1% | +9.6% | +2.4% | +9.7% | +5.0% | +10.5% |
| EPS (₹) | 4.40 | 0.80 | 0.27 | 1.22 | 0.78 | 2.20 |
| Balance sheet | ||||||
| Total assets | - | 812 | 269 | 101 | 48.50 | 13.17 |
| Net worth | - | 708 | 168 | 38.93 | 33.69 | 9.47 |
| Total debt | - | 103 | 101 | 60.66 | 14.75 | 3.71 |
| Cash & bank | - | 360 | 10.45 | 0.09 | 1.41 | 1.64 |
| Net working capital | - | 390 | 23.56 | 17.38 | 7.31 | 6.41 |
| Cash flow | ||||||
| Cash from operations | - | (20.40) | (19.26) | (47.78) | (24.06) | (2.87) |
| Cash from investing | - | (163) | (57.07) | 1.07 | (10.05) | (4.37) |
| Cash from financing | - | 533 | 86.68 | 45.33 | 33.88 | 8.50 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.99 | 36.81 | 25.15 | 35.33 | 16.13 | 11.86 | 9.59 | 9.63 |
| Revenue growth (YoY) | +67.3% | +210.4% | +162.3% | +266.9% | +115.6% | - | - | - |
| Other income | 9.55 | 22.19 | 13.38 | 11.36 | 12.08 | 9.25 | 7.19 | 3.09 |
| Total expenses | 29.32 | 40.29 | 29.69 | 33.81 | 20.98 | 14.60 | 12.01 | 10.97 |
| EBITDA | (2.33) | (3.48) | (4.54) | 1.52 | (4.85) | (2.74) | (2.42) | (1.34) |
| EBITDA margin | -8.6% | -9.5% | -18.1% | +7.3% | -30.1% | -23.1% | -25.2% | -13.9% |
| Depreciation | 3.61 | 4.13 | 3.58 | 3.65 | 1.88 | 1.27 | 0.75 | 0.53 |
| Interest | 2.22 | 1.89 | 1.75 | 1.58 | 1.76 | 2.35 | 2.70 | 0.68 |
| Profit before tax | 1.39 | 12.69 | 3.51 | 7.65 | 3.59 | 2.89 | 1.32 | 0.54 |
| Tax | 0.36 | 4.21 | 0.86 | 1.22 | 0.89 | 0.88 | 0.25 | 0.24 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 25 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 180 | 175 | 171 | 162 | 133 | 114 | 103 | 101 |
| Revenue growth (YoY) | +36.0% | +53.4% | +65.9% | +60.8% | +64.9% | - | - | - |
| Other income | 2.81 | 17.67 | 7.39 | 5.41 | 8.79 | 11.77 | 5.16 | 1.86 |
| EBITDA | 53.76 | 47.49 | 50.40 | 49.51 | 28.73 | 19.44 | 25.69 | 23.27 |
| EBITDA margin | +29.8% | +27.1% | +29.5% | +32.3% | +21.7% | +17.0% | +24.9% | +23.7% |
| Depreciation | 9.94 | 9.30 | 7.86 | 8.09 | 5.99 | 5.23 | 4.20 | 3.89 |
| Interest | 7.17 | 8.46 | 5.33 | 6.19 | 5.04 | 5.30 | 6.16 | 5.27 |
| Profit before tax | 39.46 | 47.40 | 44.60 | 40.64 | 26.49 | 20.68 | 20.49 | 15.97 |
| Tax | 9.01 | 10.73 | 11.02 | 10.52 | 5.31 | 2.71 | 4.06 | 2.90 |
| Net profit | 30.45 | 36.67 | 33.58 | 30.12 | 21.18 | 17.97 | 16.43 | 13.07 |
| EPS (₹) | 6.60 | 7.96 | 7.29 | 6.54 | 4.60 | 3.81 | 5.04 | 3.92 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 633 | 398 | 215 | 35.34 | 14.17 |
| Revenue growth | +58.9% | +85.7% | +507.0% | +149.4% | - |
| Other income | 47.06 | 19.26 | 2.82 | 3.68 | 0.46 |
| Total expenses | 464 | 309 | 173 | 22.66 | 12.21 |
| Employee cost | 0.00 | 60.37 | 35.46 | 4.79 | 2.86 |
| EBITDA | 168 | 89.70 | 41.59 | 12.68 | 1.96 |
| EBITDA margin | +26.6% | +22.5% | +19.4% | +35.9% | +13.8% |
| Depreciation | 31.25 | 16.84 | 10.02 | 1.78 | 0.71 |
| Interest | 25.03 | 21.55 | 9.45 | 2.14 | 0.57 |
| Profit before tax | 159 | 70.57 | 24.94 | 12.44 | 1.14 |
| Tax | 37.58 | 12.23 | (7.77) | 4.01 | 0.15 |
| Net profit | 115 | 58.56 | 31.48 | 8.43 | 0.99 |
| Net profit margin | +18.2% | +14.7% | +14.7% | +23.9% | +7.0% |
| EPS (₹) | 26.39 | 12.72 | 10.31 | 8.59 | 1.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | - | 46.05 | 30.51 | 9.82 | 8.74 |
| Reserves & surplus | - | 740 | 174 | 35.68 | 27.85 |
| Shareholders' funds (net worth) | - | 786 | 204 | 45.50 | 36.59 |
| Minority interest | - | 26.06 | 27.44 | 0.00 | 0.00 |
| Secured loans | - | 195 | 76.17 | 3.16 | 1.99 |
| Unsecured loans | - | 120 | 181 | 59.44 | 12.76 |
| Total debt | - | 315 | 258 | 62.60 | 14.75 |
| Total liabilities | - | 1,130 | 491 | 108 | 51.40 |
| Assets | |||||
| Gross block | - | 331 | 248 | 30.30 | 8.17 |
| Net block | - | 301 | 235 | 27.24 | 6.89 |
| Capital work in progress | - | 172 | 97.09 | 34.46 | 8.06 |
| Investments | - | 0.01 | 0.01 | 16.45 | 15.41 |
| Inventories | - | 56.63 | 37.37 | 3.12 | 2.98 |
| Sundry debtors | - | 124 | 112 | 22.11 | 19.63 |
| Cash & bank balances | - | 386 | 13.06 | 0.10 | 3.22 |
| Loans & advances | - | 156 | 88.47 | 26.01 | 1.22 |
| Total current assets | - | 722 | 251 | 51.34 | 27.05 |
| Total current liabilities | - | 96.61 | 131 | 20.61 | 7.76 |
| Net working capital | - | 626 | 120 | 30.73 | 19.29 |
| Total assets | - | 1,130 | 491 | 108 | 51.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | - | 7.65 | 0.10 | 3.22 | 1.64 |
| Net cash from operating activities | - | (45.92) | (25.70) | (1.08) | (10.45) |
| Net cash from investing activities | - | (429) | (53.73) | (48.29) | (24.44) |
| Net cash from financing activities | - | 573 | 86.98 | 46.25 | 36.46 |
| Net change in cash | - | 97.73 | 7.55 | (3.12) | 1.58 |
| Closing cash | - | 386 | 13.06 | 0.10 | 3.22 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +58.9% | +85.7% | +507.0% | +149.4% | - |
| EBITDA growth | +87.7% | +115.7% | +228.0% | +546.9% | - |
| PBT growth | +125.5% | +183.0% | +100.5% | +991.2% | +9997.0% |
| Net income growth | +97.0% | +86.0% | +273.4% | +751.5% | - |
| Revenue CAGR (3Y) | +161.6% | +204.0% | - | - | - |
| EBITDA CAGR (3Y) | +136.8% | +257.7% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +19.2% | +14.7% | +15.3% | +23.9% | +7.0% |
| Return on capital employed | - | +11.8% | +12.0% | +18.2% | +3.3% |
| Return on net worth | - | +11.8% | +26.2% | +20.5% | +2.7% |
| Debt / equity | - | 0.58 | 1.28 | 0.94 | 0.40 |
| Long-term debt / equity | - | 0.32 | 0.60 | 0.12 | 0.07 |
| Interest cover | 18.26 | 29.58 | 29.93 | 19.63 | 45.60 |
| Efficiency & per share | |||||
| Fixed asset turnover | - | 1.38 | 1.54 | 1.84 | 1.73 |
| Inventory turnover | - | 8.47 | 10.60 | 11.59 | 4.76 |
| Debtors turnover | - | 3.38 | 3.20 | 1.69 | 0.72 |
| EPS (₹) | 26.39 | 12.72 | 10.31 | 8.59 | 1.13 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 170.72 | 66.95 | 46.36 | 41.86 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.99 | 36.81 | 25.15 | 35.33 | 16.13 | 11.86 | 9.59 | 9.63 |
| Revenue growth (YoY) | +67.3% | +210.4% | +162.3% | +266.9% | +115.6% | - | - | - |
| Other income | 9.55 | 22.19 | 13.38 | 11.36 | 12.08 | 9.25 | 7.19 | 3.09 |
| Total expenses | 29.32 | 40.29 | 29.69 | 33.81 | 20.98 | 14.60 | 12.01 | 10.97 |
| EBITDA | (2.33) | (3.48) | (4.54) | 1.52 | (4.85) | (2.74) | (2.42) | (1.34) |
| EBITDA margin | -8.6% | -9.5% | -18.1% | +7.3% | -30.1% | -23.1% | -25.2% | -13.9% |
| Depreciation | 3.61 | 4.13 | 3.58 | 3.65 | 1.88 | 1.27 | 0.75 | 0.53 |
| Interest | 2.22 | 1.89 | 1.75 | 1.58 | 1.76 | 2.35 | 2.70 | 0.68 |
| Profit before tax | 1.39 | 12.69 | 3.51 | 7.65 | 3.59 | 2.89 | 1.32 | 0.54 |
| Tax | 0.36 | 4.21 | 0.86 | 1.22 | 0.89 | 0.88 | 0.25 | 0.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 106 | 38.54 | 34.01 | 12.38 | 13.54 | 7.91 |
| Revenue growth | +175.3% | +13.3% | +174.7% | -8.6% | +71.2% | - |
| Other income | 66.35 | 21.99 | 6.84 | 6.79 | 0.94 | 0.15 |
| Total expenses | 125 | 45.82 | 34.07 | 14.16 | 12.38 | 6.90 |
| Employee cost | 0.00 | 18.25 | 9.35 | 5.02 | 2.86 | 1.63 |
| EBITDA | (18.68) | (7.28) | (0.06) | (1.78) | 1.16 | 1.01 |
| EBITDA margin | -17.6% | -18.9% | -0.2% | -14.4% | +8.6% | +12.8% |
| Depreciation | 13.23 | 3.08 | 2.04 | 0.93 | 0.71 | 0.57 |
| Interest | 6.98 | 6.52 | 2.71 | 2.14 | 0.56 | 0.20 |
| Profit before tax | 27.46 | 5.11 | 2.03 | 1.94 | 0.83 | 0.39 |
| Tax | 7.21 | 1.42 | 1.22 | 0.74 | 0.15 | (0.44) |
| Net profit | 20.25 | 3.69 | 0.81 | 1.20 | 0.68 | 0.83 |
| Net profit margin | +19.1% | +9.6% | +2.4% | +9.7% | +5.0% | +10.5% |
| EPS (₹) | 4.40 | 0.80 | 0.27 | 1.22 | 0.78 | 2.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | - | 46.05 | 30.51 | 9.82 | 8.74 | 3.80 |
| Reserves & surplus | - | 662 | 138 | 29.11 | 24.95 | 5.67 |
| Shareholders' funds (net worth) | - | 708 | 168 | 38.93 | 33.69 | 9.47 |
| Secured loans | - | 52.81 | 14.91 | 3.01 | 1.99 | 0.49 |
| Unsecured loans | - | 49.93 | 85.78 | 57.65 | 12.76 | 3.22 |
| Total debt | - | 103 | 101 | 60.66 | 14.75 | 3.71 |
| Total liabilities | - | 812 | 269 | 101 | 48.50 | 13.17 |
| Assets | ||||||
| Gross block | - | 61.90 | 28.34 | 8.29 | 2.87 | 2.26 |
| Net block | - | 54.59 | 24.09 | 7.77 | 1.59 | 1.69 |
| Capital work in progress | - | 34.01 | 18.47 | 11.33 | 3.17 | 2.71 |
| Investments | - | 104 | 81.58 | 8.23 | 11.69 | 1.45 |
| Inventories | - | 8.66 | 4.52 | 3.12 | 2.98 | 0.34 |
| Sundry debtors | - | 25.69 | 22.01 | 15.73 | 8.37 | 0.23 |
| Cash & bank balances | - | 360 | 10.45 | 0.09 | 1.41 | 1.64 |
| Loans & advances | - | 18.00 | 2.98 | 8.74 | 1.22 | 5.98 |
| Total current assets | - | 412 | 39.96 | 27.68 | 13.98 | 8.19 |
| Total current liabilities | - | 21.87 | 16.40 | 10.30 | 6.67 | 1.78 |
| Net working capital | - | 390 | 23.56 | 17.38 | 7.31 | 6.41 |
| Total assets | - | 812 | 269 | 101 | 48.50 | 13.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | - | 10.44 | 0.09 | 1.41 | 1.64 | 0.39 |
| Net cash from operating activities | - | (20.40) | (19.26) | (47.78) | (24.06) | (2.87) |
| Net cash from investing activities | - | (163) | (57.07) | 1.07 | (10.05) | (4.37) |
| Net cash from financing activities | - | 533 | 86.68 | 45.33 | 33.88 | 8.50 |
| Net change in cash | - | 349 | 10.35 | (1.38) | (0.23) | 1.25 |
| Closing cash | - | 360 | 10.45 | 0.09 | 1.41 | 1.64 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +175.3% | +13.3% | +174.7% | -8.6% | +71.2% | - |
| EBITDA growth | -156.6% | - | +96.6% | -253.5% | +14.9% | - |
| PBT growth | +437.4% | +151.7% | +4.6% | +133.7% | +112.8% | +9997.0% |
| Net income growth | +448.8% | +355.6% | -32.5% | +76.5% | -18.1% | - |
| Revenue CAGR (3Y) | +104.6% | +41.7% | +62.6% | - | - | - |
| EBITDA CAGR (3Y) | +118.9% | - | - | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +19.1% | +9.6% | +2.4% | +9.7% | +5.0% | +10.5% |
| Return on capital employed | - | +2.2% | +2.6% | +5.4% | +4.5% | +4.6% |
| Return on net worth | - | +0.8% | +0.8% | +3.3% | +3.2% | +8.9% |
| Debt / equity | - | 0.23 | 0.78 | 1.04 | 0.43 | 0.39 |
| Long-term debt / equity | - | 0.13 | 0.13 | 0.04 | 0.13 | 0.34 |
| Interest cover | -21.87 | -62.93 | -129.05 | -78.97 | 124.44 | 45.45 |
| Efficiency & per share | ||||||
| Fixed asset turnover | - | 0.85 | 1.86 | 2.22 | 5.28 | 3.50 |
| Inventory turnover | - | 5.85 | 8.90 | 4.06 | 8.16 | 23.26 |
| Debtors turnover | - | 1.62 | 1.80 | 1.03 | 3.15 | 34.39 |
| EPS (₹) | 4.40 | 0.80 | 0.27 | 1.22 | 0.78 | 2.20 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 153.74 | 55.10 | 39.66 | 38.54 | 24.91 |
To see the full year-wise statements and ratios of Senores Pharmaceuticals Limited, buy the company report.
Board of directors of Senores Pharmaceuticals Limited
Senores Pharmaceuticals has 12 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashokkumar Vijaysinh Barot Also directs: Aviraj Ventures LLP, Di- Cal Pharma Private Limited, Tierra Fertilizer Private Limited and 1 more | Director | 15 May 2018 | 8 Years 5 Months | Current |
| Deval Rajnikant Shah | Whole-Time Director | 01 Jan 2020 | 6 Years 9 Months | Current |
| Jitendra Babulal Sanghvi Also directs: Ratnatris Pharmaceuticals Private Limited | Director | 23 Nov 2021 | 4 Years 11 Months | Current |
| Swapnil Jatinbhai Shah Also directs: Ratnatris Pharmaceuticals Private Limited, Espee Therapeutics LLP, Aelius Projects LLP and 4 more | Managing Director | 15 Oct 2021 | 5 Years 0 Months | Current |
| Manjula Devi Shroff Also directs: Meghmani Industries Limited, Allen Enterprises Private Limited, Kahini Edtech Private Limited and 4 more | Director | 30 Jan 2024 | 2 Years 8 Months | Current |
| Kalpit Rajesh Gandhi Also directs: Ratnatris Pharmaceuticals Private Limited, Karman Developers LLP, Vadilal Enterprises Limited and 5 more | Director | 30 Jan 2024 | 2 Years 8 Months | Current |
Showing 6 of 12 current directors. View all directors
Peer comparison
Senores Pharmaceuticals Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Senores Pharmaceuticals Limitedthis company | ₹632.63 Cr (FY 2026) | ₹115.36 Cr | 18.2% | 58.9% | 120 | Ahmedabad, Gujarat, India |
| Olon Active Pharmaceutical Ingredients India Private Limited | ₹431.21 Cr (FY 2025) | 11.0% | Thane, Maharashtra, India | |||
| Sterling Biotech Limited | ₹428.01 Cr (FY 2025) | -10.0% | Mumbai, Maharashtra, India | |||
| Visa Drugs & Pharmaceuticals Private Limited | ₹414.04 Cr (FY 2016) | 32.0% | Kolkata, West Bengal, India | |||
| Themis Medicare Limited | ₹410.18 Cr (FY 2025) | 6.0% | Vapi, Gujarat, India | |||
| Skymap Pharmaceuticals Private Limited | ₹409.08 Cr (FY 2025) | 2.0% | New Delhi, Delhi, India | |||
| Penam Laboratories Limited | ₹407.63 Cr (FY 2025) | -26.0% | New Delhi, Delhi, India | |||
| Torque Pharmaceuticals Private Limited | ₹404.13 Cr (FY 2024) | 1.0% | Chandigarh, India |
To see the full peer comparison of Senores Pharmaceuticals Limited, buy the company report.
Auditor
Senores Pharmaceuticals Limited is audited by PANKAJ R SHAH & ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PANKAJ R SHAH & ASSOCIATES | FY 2024 | 107361W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 45.80%, foreign institutional investors hold 6.60%, domestic institutional investors hold 9.80% and retail and other public shareholders hold 37.80%.
Sep 2026
QUARTER
45.80% Promoters
9.80% DII (Domestic Institutional)
6.60% FII (Foreign Institutional)
37.80% Retail & Others
Promoter holding - history
Now 45.80% · Sep 2026High 45.80% · Dec 2025Low 45.80% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 45.80% | 45.80% | 45.80% | 45.80% |
| Public | 54.20% | 54.20% | 54.20% | 54.20% |
Charges & borrowings
Open charges
₹210.24 Cr
Satisfied charges
₹130.75 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 22 Jun 2026 | 101315488 | Hdfc Bank Limited | ₹32.42 Lakh | Open | |
| 12 Jun 2026 | 101318113 | Hdfc Bank Limited | ₹2.56 Cr | Open | |
| 07 May 2026 | 101300110 | Others | ₹35 Cr | Open | |
| 12 Mar 2026 | 101253811 | Hdfc Bank Limited | ₹27.23 Lakh | Open | |
| 13 Nov 2025 | 101189074 | Hdfc Bank Limited | ₹23 Lakh | Open |
To see the full charge records of Senores Pharmaceuticals Limited, buy the company report.
Total charge records: 15 View all charges
Deals & funding
Senores Pharmaceuticals Limited has 18 deals on record (11 market trades, 4 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹28.28 Cr; the latest was in December 2025.
Total deals
18
Market trades
11
Funding rounds
4
Convertible or debt financing
1
IPO
1
Disclosed funding
₹28.28 Cr
Deals on record (5 of 18)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2025 | Market trade | ₹40.28 Cr | Buyer: Graviton Research Capital LLP , Hrti Private Limited Seller: Graviton Research Capital LLP , Hrti Private Limited |
| Jul 2025 | Market trade | ₹60.78 Cr | Buyer: Graviton Research Capital LLP , Qe Securities LLP Seller: Graviton Research Capital LLP , Qe Securities LLP |
| Mar 2025 | Market trade | ₹15.12 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Feb 2025 | Market trade | ₹52.26 Cr | Buyer: Graviton Research Capital LLP , Hrti Private Limited , Qe Securities LLP Seller: Graviton Research Capital LLP , Qe Securities LLP , Hrti Private Limited |
| Jan 2025 | Market trade | ₹14.11 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
To see the full deal history of Senores Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Senores Pharmaceuticals Limited has 3 court cases on record: 3 filed by Senores Pharmaceuticals. All cases are pending.
Total cases
3
Filed by the company
3
Pending
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 0 | 3 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed by the company against Wipro Pharmatech-Ranjit Kumar | Pending |
| District court, Ahmedabad, Gujarat | Court case (CR EN) | Filed by the company against Phoenix Pharma - Kailashchandra Rawal | Pending |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed by the company against Hub Pharma-Suraj T Chirankar | Pending |
To see the full case history of Senores Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Senores Pharmaceuticals Limited has 7 MSME Form 1 returns on record between 2021 and 2024, listing 58 overdue payments to 12 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 12)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Penta Freight Private Limited | |||
| All Four Season Travels | |||
| B J Patel & J L Shah | |||
| an individual supplier | |||
| Aelius Projects LLP |
To see the full MSME payment records of Senores Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Senores Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Ratnatris Pharmaceuticals Private Limited | U24230GJ2005PTC047394 |
To see the full group structure of Senores Pharmaceuticals Limited, buy the company report.
Employees & EPFO
Senores Pharmaceuticals Limited has a workforce of 120 employees on its EPFO records as of Feb 10, 2025, across 1 active EPFO establishment.
Employee count
120
Active EPFO establishments
1
Employee growth
150%
GST
Senores Pharmaceuticals has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAZCS6422N1ZK | Gujarat | Active | 01 Mar 2018 |
| 27AAZCS6422N1ZE | Maharashtra | Active | 10 Mar 2025 |
To see the full GST registrations and return filing status of Senores Pharmaceuticals Limited, buy the company report.
Recent activity
Senores Pharmaceuticals Limited has 24 board changes on record since 2017: 18 appointments and 6 cessations. The latest: Udayan Dileep Choksi was appointed as Director on 08 Mar 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.32 Cr with Charge ID 101315488 was registered on 22 Jun 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 2.56 Cr with Charge ID 101318113 was registered on 12 Jun 2026.
Charges
A charge with Others of Rs. 45.00 Cr registered on 13 Feb 2025 with Charge ID 101053565 was modified on 13 May 2026.
Charges
A charge with Others amounted to Rs. 35.00 Cr with Charge ID 101300110 was registered on 07 May 2026.
Charges
A charge with Hdfc Bank Limited of Rs. 120.94 Cr registered on 31 Dec 2022 with Charge ID 100668335 was modified on 20 Apr 2026.
Filing
Senores Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.27 Cr with Charge ID 101253811 was registered on 12 Mar 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.23 Cr with Charge ID 101189074 was registered on 13 Nov 2025.
AGM
Senores Pharmaceuticals Limited last Annual general meeting of members was held on 18 Sep 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.45 Cr with Charge ID 101113826 was registered on 26 Jun 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.35 Cr with Charge ID 101087233 was registered on 02 May 2025.
Charges
A charge registered on 05 Oct 2024 via Charge ID 100984798 with Others was fully satisfied on 17 Mar 2025.
38 earlier events are in the company report.
News
Senores Pharma: Board Greenlights Reappointments Of Managing Director And Whole Time Director; Swapnil Jatinbhai Shah For Three Years Starting October 15, 2026; Chetan Bipinchandra Shah For Three Years Starting November 10, 2026, Both Awaiting Shareholder Approval.
Frequently asked questions
Senores Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 26 December 2017 (9+ years old) and is registered under CIN L24290GJ2017PLC100263. Listed on BSE: 544319 and NSE: SENORES.
Senores Pharmaceuticals reported revenue of ₹632.63 Cr for FY 2025-26 (up 58.9% YoY) based on consolidated financials.
Senores Pharmaceuticals has 12 current directors:
- Swapnil Jatinbhai Shah - Managing Director
- Deval Rajnikant Shah - Whole-Time Director
- Chetan Bipinchandra Shah - Whole-Time Director
- Ashokkumar Vijaysinh Barot - Director
- Jitendra Babulal Sanghvi - Director
- Manjula Devi Shroff - Director
- Kalpit Rajesh Gandhi - Director
- Naresh Bansilal Shah - Director
- Udayan Dileep Choksi - Director
- Arpit Deepakkumar Shah - Director
- Hemanshu Nitinchandra Pandya - Director
- Sanjay Shaileshbhai Majmudar - Director
The latest financial statements of Senores Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 18 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Senores Pharmaceuticals is 24AAZCS6422N1ZK, registered in Gujarat. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 27AAZCS6422N1ZE (Maharashtra).
The CIN (Corporate Identification Number) of Senores Pharmaceuticals is L24290GJ2017PLC100263. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Senores Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 544319) and NSE (symbol: SENORES).
Senores Pharmaceuticals has 3 court cases on record: 3 filed by the company. 3 are pending.
Senores Pharmaceuticals was incorporated on 26 December 2017, making it 9+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Senores Pharmaceuticals has 18 deals on record (11 market trades, 4 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹28.28 Cr; the latest was in December 2025.
The peers of Senores Pharmaceuticals by revenue are Olon Active Pharmaceutical Ingredients India Private Limited, Sterling Biotech Limited, Visa Drugs & Pharmaceuticals Private Limited, Themis Medicare Limited, Skymap Pharmaceuticals Private Limited and 2 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Udayan Dileep Choksi was appointed as Director on 08 Mar 2024. Sanjay Shaileshbhai Majmudar was appointed as Director on 10 Feb 2024. Kalpit Rajesh Gandhi was appointed as Director on 30 Jan 2024. Senores Pharmaceuticals has 24 board changes on record in total.